Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients

Diabetes Clinical Trial

Official title:

Open-label, Single-dose Study of Polysaccharide Superparamagnetic Iron Oxide Injection for Contrast-enhanced Cardiovascular Magnetic Resonance Imaging in Patients With Type 2 Diabetes and Chronic Kidney Disease.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06051565
• Other study ID #: DJTCSCYHT-I-03
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 6, 2021
• Est. completion date: September 15, 2022

Study information

• Verified date: October 2021
• Source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single-center, single-dose study aims to evaluate the effect and safety of polymeric superparamagnetic iron oxide in cardiovascular magnetic resonance imaging for diabetic patients with concomitant chronic kidney disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: September 15, 2022
• Est. primary completion date: June 13, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Aged = 18 years, = 80 years.
• Patients who have been diagnosed with chronic kidney disease (CKD) according to diagnostic criteria, meeting at least one CKD diagnostic criterion.
• Patients with a confirmed history of atherosclerosis and/or chronic venous disease (including deep vein thrombosis, thrombotic venous inflammation, lower limb varicose veins, etc.) either in their medical history or diagnosed during hospital admission, and within the past year, at least one imaging examination has confirmed the presence

of at least one of the following vascular abnormalities in at least one vascular bed:

1. =50% vascular stenosis;

2. Arterial aneurysm;

3. Arterial dissection;

4. Arteriovenous malformation;

5. Arteriovenous fistula;

6. Vascular developmental abnormalities;

7. Varicose veins, etc. For details, please refer to the inclusion criteria section.

• Patients capable of self-care in daily life.
• Patients who voluntarily agree to participate in this study, sign an informed consent form, have a full understanding of the trial's content, procedures, and potential adverse reactions, and demonstrate good compliance.
• Patients who are unwilling to sign an informed consent form for the exploratory research can still be enrolled in the main study.
• Subjects who have no plans for pregnancy for at least 2 weeks before self-administration of the investigational drug and for at least 6 months after the last use of the investigational drug and voluntarily agree to adopt effective contraceptive measures.

Exclusion Criteria:

• Patients who have undergone stent implantation for vascular treatment in the target vascular bed.
• Patients who have had or currently have malignant tumors within the last 3 years.
• Serum ferritin > 1000 µg/L.
• Patients who are planned to undergo magnetic resonance imaging (MRI) examination for various reasons during the trial.
• Blood donation or significant blood loss (> 450 ml) within the two months before medication.
• Patients with a history of substance abuse involving psychotropic drugs and are unable to quit or have psychiatric disorders.
• Patients with any severe and/or uncontrolled diseases, including:

1. Outpatients diagnosed through medical history; inpatients diagnosed based on past medical history and current medical history indicating = Grade 2 myocardial ischemia or myocardial infarction, = Grade 2 congestive heart failure (New York Heart Association (NYHA) classification).

2. Active or uncontrolled severe systemic infections (= Common Terminology Criteria for Adverse Events (CTCAE) 5.0 Grade 2).

• Infectious diseases such as cirrhosis, active hepatitis*, syphilis, human immunodeficiency virus (HIV), etc. *Reference for hepatitis B: hepatitis B surface antigen (HBsAg) positive and Hepatitis B Virus (HBV) DNA test value exceeds the upper limit of normal; Reference for hepatitis C: Hepatitis C Virus (HCV) antibody positive and HCV viral titer test value exceeds the upper limit of normal.
• History of immunodeficiency, acquired or congenital immunodeficiency diseases, or organ transplantation.
• Pregnancy or currently breastfeeding or planning to breastfeed during the study.
• Presence of metal objects in the body (dentures, contraceptive rings, metal implants, metal clips, etc.) and claustrophobia.
• Allergic reactions to the investigational drug, its metabolites, or excipients.
• Use of the investigational drug or participation in drug clinical trials within the two months before medication.
• Difficulty with or intolerance to MRI scans.
• Subjects who cannot or will not comply with the hospital management regulations.
• According to the investigator's judgment, patients with accompanying diseases that pose a serious risk to patient safety or may interfere with the completion of the study, or patients deemed unsuitable for inclusion for other reasons.

Related Conditions & MeSH terms

• Diabetes
• Magnetic Resonance Imaging

Intervention

Drug:
• Polysaccharide superparamagnetic iron oxide injection
Polysaccharide superparamagnetic iron oxide injection can be used for the treatment of iron-deficiency anemia and for magnetic resonance imaging enhancement.

Locations

Country	Name	City	State
China	Beijing Luhe Hospital, Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of vascular segments with lesions	The number of vascular segments with lesions after administration	0 hour after administration
Primary	Lesion length	Vascular lesion length	0 hour after administration
Primary	Degree of vascular stenosis	Vascular stenosis degree	0 hour after administration
Secondary	Image quality scores	Vascular image quality was scored on a 4-point scale. 1 = Vessels not assessable due to poor image quality; 2 = Vessels visualized but only gross features (size/patency) confidently assessable; 3 = Vessels well defined and evaluable for structural pathology with high confidence; 4 = Excellent vessel definition with sharp borders such that fine details can be evaluated with high confidence.	0 hour after administration
Secondary	Myocardium T1 values	Changes from baseline in the longitudinal relaxation value of myocardial tissue.	0 hour after administration
Secondary	Signal-to-noise ratio	The strength of a signal relative to the background noise.	0 hour after administration
Secondary	Contrast-to-noise ratio	The visibility and distinguishability of structures or features of interest in an image in the presence of noise.	0 hour after administration
Secondary	Adverse event rate	The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).	Baseline up to 24 hours after administration
Secondary	Serum iron	Changes from baseline in the amount of circulating iron that is bound to transferrin and freely circulate in the blood.	Baseline up to 24 hours after administration
Secondary	Serum ferritin	Changes from baseline in the concentration of plasma (or serum) ferritin.	Baseline up to 30 days and 60 days after administration
Secondary	Total iron-binding capacity	Changes from baseline in the total amount of iron that can be bound by transferrin proteins in the blood.	Baseline up to 30 days and 60 days after administration
Secondary	Serum transferrin saturation	Changes from baseline in the value of serum iron divided by the total iron-binding.	Baseline up to 30 days and 60 days after administration